CA2671357C — Crystalline form of 1-(.beta.-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Assigned to Tanabe Pharma Corp · Expires 2011-11-01 · 15y expired
What this patent protects
A novel crystal form of a hemihydrate of the compound 1-(.beta.-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene of formula (I): (see formula I) and having favorable characteristics, is characterized by its X-ray powder diffraction pattern and/or by it…
USPTO Abstract
A novel crystal form of a hemihydrate of the compound 1-(.beta.-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene of formula (I): (see formula I) and having favorable characteristics, is characterized by its X-ray powder diffraction pattern and/or by its infrared spectrum.
Drugs covered by this patent
- Invokana (CANAGLIFLOZIN) · Johnson & Johnson
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.